Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Dx Firm Navignostics Raises CHF 7.5 M in Seed Funding From Bruker, Others

NEW YORK – Swiss precision oncology diagnostics company Navignostics said Wednesday it has raised CHF 7.5 million ($7.6 million) in seed funding to develop its single-cell spatial proteomics platform.

The oversubscribed round was led by Bruker and joined by Think.Health Ventures, Ventura Biomed Investors, and Zürcher Kantonalbank.

Zurich-based Navignostics, a 2022 spinout from the lab of University of Zurich researcher Bernd Bodenmiller, is developing a system that combines single-cell spatial proteomic data with artificial intelligence analysis to guide targeted and immunotherapy selection for cancer patients.

"With this seed financing, we will boost our capacity to engage with clinical, biotech, and pharma partners and accelerate the development of our first diagnostic product," Jana Fischer, Navignostics' cofounder and CEO, said in a statement. "We will take a big step in Navignostics’ company expansion by moving our team into our own laboratory and office premises, enabling the establishment of certified processes and further expansion of our world-leading team of scientists and business professionals."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.